Boron Neutron Capture Therapy: A New Chapter in the Treatment of Resistant Tumors

Boron Neutron Capture Therapy (BNCT) stands as a cuttingedge approach to cancer treatment, offering a targeted method with minimal side effects. This innovative technique utilizes boron-10 and neutron irradiation to selectively destroy cancer cells while preserving healthy tissue [1,2]. The concept and principles of neutron capture therapy were initially elucidated by Locher in 1936 [3]. The inaugural clinical trial of BNCT was initiated by Farr and Sweet et al. in 1951, utilizing the Brookhaven Graphite Research Reactor to treat GBM [4]. BNCT operates on a simple yet ingenious principle, in which aboron-10, a non-radioactive isotope, accumulates in a target cell, and when exposed to lowenergy neutrons, boron-10 captures a neutron and spontaneously undergoes a nuclear reaction, emitting high-energy alpha particles and recoiling lithium nuclei. Since the path length of these high LET particles is around 5-9 microns, the damage remains in the targeted cell, sparing the non-boron-10-containing surrounding healthy cells. This targeted approach minimizes collateral damage to surrounding tissues, thereby reducing the debilitating side effects commonly associated with traditional cancer treatments such as chemotherapy and radiotherapy [2,5]. In this opinion piece, we explore the intricacies of BNCT, its potential benefits, challenges, and its future prospects.

One of BNCT’s most compelling advantages lies in its ability to treat highly invasive and resistant tumors that have proven refractory to other therapies. Unlike conventional treatments, which often rely on the indiscriminate destruction of rapidly dividing cells, BNCT offers a precise and tailored approach that can effectively eradicate even the most aggressive cancerous growths [2]. Moreover, BNCT holds great promise for treating tumors located in critical or inaccessible areas of the body, such as the brain, spine, and head and neck regions, where surgery and conventional radiotherapy pose significant risks to surrounding healthy tissues and vital structures [2]. Furthermore, BNCT exhibits remarkable versatility, with the potential to be combined synergistically with other treatment modalities to enhance therapeutic outcomes. By exploiting the complementary mechanisms of action of different therapies, such as chemotherapy, immunotherapy, and targeted molecular agents, BNCT can potentially overcome treatment resistance and improve patient responses [6]. This multidisciplinary approach underscores the adaptability and efficacy of BNCT in addressing the complex and heterogeneous nature of cancer.

Despite its immense therapeutic potential, BNCT faces several challenges that must be addressed to realize its widespread clinical adoption. Foremost among these is the development of optimized boron delivery agents capable of efficiently targeting tumor cells while minimizing off-target effects. Current strategies primarily rely on boron-containing compounds such as Boronophenylalanine (BPA) and sodium borocaptate (BSH), which exhibit varying degrees of tumor selectivity and pharmacokinetic properties [2]. Research efforts focused on refining the pharmacological properties, biodistribution, and tumor uptake of these agents are essential for enhancing the efficacy and safety of BNCT. In addition, the availability of suitable neutron sources represents a significant logistical hurdle for the widespread implementation of BNCT. While research reactors and particle accelerators capable of producing therapeutic neutron beams exist, their accessibility and cost-effectiveness limit the scalability of BNCT [5,7]. Collaborative initiatives involving government agencies, research institutions, and private sector stakeholders are needed to overcome these infrastructural barriers and establish dedicated BNCT facilities equipped with optimized neutron sources and treatment delivery systems. To effectively apply BNCT, it’s crucial to address key factors throughout its design and implementation stages. These include factors like lesion location and depth, absorption of the boron-10 delivery agent, neutron beam irradiation cycle and intensity, and pharmacokinetics [8]. Previous studies by Joensuu and colleagues at the University of Helsinki have extensively investigated the metabolism and toxicity of various boron delivery agents. For instance, they controlled the concentration and injection rate of paraboron-phenylalanine (BPA)-fructose (BPA-F) below 500 mg/kg/h and gathered substantial clinical data, showcasing the therapy’s feasibility and offering valuable insights for further research [9].

Despite many advancements, BNCT remains underutilized due to limited experience in drug utilization, challenges in patient recruitment, insufficient medical neutron sources, and other factors. Consequently, the development and clinical implementation of BNCT have progressed relatively slowly. The challenges remain on the path to widespread clinical adoption, ongoing research, and collaborative efforts are paving the way for the realization of BNCT’s full potential in the fight against cancer.

BNCT holds a great potential for enhancing the therapeutic efficacy of Radiation Therapy (RT) in the management of many cancers including radioresistant. By exploiting the synergistic effects of boron-10-mediated neutron capture and conventional photon or proton irradiation, BNCT can augment the DNA damage inflicted upon cancer cells, leading to enhanced tumor control rates and reduced risk of recurrence. This combination approach, known as Boron-enhanced Radiation Therapy (BERT), capitalizes on the complementary mechanisms of action of boron neutron capture and external beam radiation, thereby overcoming inherent limitations associated with each modality alone. The synergistic interaction between BNCT and RT underscores the versatility and adaptability of BNCT as part of a multimodal treatment strategy tailored to individual patient needs [10].

Moreover, BNCT holds promise for expanding the therapeutic armamentarium against metastatic cancers, which pose a significant clinical challenge due to their propensity for widespread dissemination and resistance to conventional therapies. The ability of BNCT to selectively target metastatic lesions while sparing normal tissues offers a unique opportunity to eradicate residual disease burden and prevent disease progression. Furthermore, BNCT is typically given as a single treatment vs multiple rounds of fractionated radiation dose in combination with systemic chemotherapy makes it an attractive option for patients with advanced-stage disease who may have limited treatment options and poor tolerance to aggressive therapies. This provides favorable toxicity profile of BNCT compared to conventional RT/chemo.

The development of drugs for Boron Neutron Capture Therapy (BNCT) is hindered by the scarcity of suitable boron delivery agents, notably limited to Boronophenylalanine (BPA) and Sodium Borocaptate (BSH). While these agents have shown efficacy, they possess shortcomings, prompting the search for alternative treatments. Current agents struggle with selective tumor accumulation, necessitating high doses that may increase toxicity. To address this, researchers around the world, and in our laboratory are exploring nanotechnology-based approaches for targeted drug delivery in BNCT [11-13]. Nanoparticles offer advantages like enhanced tumor accumulation and BBB penetration, crucial for treating central nervous system tumors such as glioblastoma. Nanotechnology enables multifunctional nanocarriers for simultaneous imaging and therapy, aiding in realtime treatment monitoring. The development of nanomaterials with optimal properties for boron-10 enrichment is crucial. These nanomaterials should possess high boron loading capacities and excellent stability to ensure effective drug delivery to tumor sites. Additionally, the incorporation of targeting peptides into nanocarriers can enhance their specificity towards cancer cells, improving therapeutic efficacy while minimizing off-target effects. These peptides can selectively bind to receptors overexpressed on tumor cells, facilitating targeted drug delivery and reducing systemic toxicity [11,14]. Furthermore, overcoming the blood-brain barrier (BBB) represents a critical challenge in treating central nervous system tumors like glioblastoma. Nanocarriers engineered with BBB-penetrating capabilities, such as surface modifications with specific ligands or size optimization, can facilitate efficient drug delivery to brain tumors while minimizing systemic exposure.

In our opinion, Boron Neutron Capture Therapy (BNCT) holds significant promise for cancer treatment, offering targeted destruction of tumors with minimal side effects. Challenges such as optimized boron delivery agents and neutron source availability persist, but nanotechnology presents a hopeful solution. Combining BNCT with conventional therapies like radiation expands its potential, particularly in radioresistant and metastatic cancers. Despite hurdles, nanotechnology presents a promising solution to enhance BNCT efficacy by enabling targeted drug delivery. Nanoparticles offer advantages such as improved tumor accumulation, penetration of the BBB, and real-time treatment monitoring. Overcoming these challenges through nanotechnologybased approaches holds great promise for advancing BNCT as a potent cancer treatment modality.

We would like to acknowledge funds from NIH/NCI grant 1R1CA259911-01A1 and the Department of Basic Science, Division of Cancer Science, Loma Linda University for providing the facilities in which the manuscript was conceptualized, written, and discussed.

The authors declare no conflict of interest.

1. Zhou T, Igawa K, Tomonari K, Sadahira T, Wang W, et al. (2024) The current status and novel advances of boron neutron capture therapy clinical trials. Am J Cancer Res 14(2): 429-447.
2. Malouff TD, Danushka SS, Daniel KE, William CS, Mark R, et al. (2021) Boron Neutron Capture Therapy: A Review of Clinical Applications. Front Oncol 26: 11: 601820.
3. Locher G (1936) Biological Effects and Therapeutic Possibilities of Neutrons. Am J Roentgenol Radium Ther 36: 1-13.
4. Farr LE (1954) Neutron capture therapy of gliomas using boron. Trans Am Neurol Assoc 13(79th Meeting): 110-113.
5. Wang S, Zhang Z, Miao L, Yumin L (2022) Boron Neutron Capture Therapy: Current Status and Challenges. Front Oncol 31:12: 788770.
6. Ahire V, Bidakhvidi NA, Boterberg T, Chaudhary P, Chevalier F, et al. (2023) Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities. in Radiobiology Textbook, S Baatout (Ed) Springer 311-386.
7. Kreiner AJ, Bergueiro J, Cartelli D, Baldo M, Castell W, et al. (2016) Present status of Accelerator-Based BNCT. Rep Pract Oncol Radiother 21(2): 95-101.
8. Lan G, Song Q, Luan Y, Cheng Y (2024) Targeted strategies to deliver boron agents across the blood-brain barrier for neutron capture therapy of brain tumors. Int J Pharm 650: 123747.
9. Joensuu H, Kankaanranta L, Seppälä T, Auterinen I, Kallio M, et al. (2003) Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J Neurooncol 62(1-2): 123-134.
10. Matsumoto Y, Fukumitsu N, Ishikawa H, Nakai K, Sakurai H (2021) A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond. J Pers Med 11(8): 825.
11. Lansangan C, Khoobchandani M, Jain R, Rudensky S, Perry CC, et al. (2024) Designing Gold Nanoparticles for Precise Glioma Treatment: Challenges and Alternatives. Materials (Basel) 17(5).
12. Pulagam KR, Gona KB, Gómez-Vallejo V, Meijer J, Zilberfain C, et al. (2019) Gold Nanoparticles as Boron Carriers for Boron Neutron Capture Therapy: Synthesis, Radiolabelling and In vivo Evaluation. Molecules 24(19): 3609.
13. Beck-Sickinger AG, Becker DP, Chepurna O, Das B, Fliger S, et al. (2023) New Boron Delivery Agents. Cancer Biother Radiopharm 38(3): 160-172.
14. Ljubimova JY, Portilla-Arias J, Patil R, Ding H, Inoue S, et al. (2013) Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment. J Drug Target 21(10): 956-967.